{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.2","value":"1564.5"},{"groupId":"OG001","spread":"52.9","value":"6308.4"},{"groupId":"OG002","spread":"33.8","value":"11249.9"},{"groupId":"OG003","spread":"30.2","value":"25403.4"},{"comment":"Insufficient data to calculate geometric mean and geometric coefficient of variation","groupId":"OG004","spread":"NA","value":"NA"},{"groupId":"OG005","spread":"4.2","value":"7612.2"},{"groupId":"OG006","spread":"286.3","value":"7152.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"title":"Week 1 dose"},{"categories":[{"measurements":[{"comment":"A geometric mean coefficient of variation cannot be calculated for data from only 1 participant.","groupId":"OG000","spread":"NA","value":"2950.0"},{"groupId":"OG001","spread":"34.9","value":"9880.4"},{"groupId":"OG002","spread":"17.6","value":"10998.7"},{"groupId":"OG003","spread":"38.1","value":"25731.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"Week 9 dose (steady state)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"4"}],"units":"Participants"}],"description":"Calculated from plasma concentrations measured from samples collected at times shown below","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG000","title":"CTX-471 Monotherapy 0.1 mg/kg"},{"description":"0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG001","title":"CTX-471 Monotherapy 0.3 mg/kg"},{"description":"0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG002","title":"CTX-471 Monotherapy 0.6 mg/kg"},{"description":"1.2 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks","id":"OG003","title":"CTX-471 Monotherapy 1.2 mg/kg"},{"description":"0.1 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG004","title":"CTX-471 Combination 0.1 mg/kg"},{"description":"0.3 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG005","title":"CTX-471 Combination 0.3 mg/kg"},{"description":"0.6 mg/kg body weight of CTX-471 by IV infusion over 1 hour every 2 weeks + 400 mg of pembrolizumab by IV infusion over 30 minutes every 6 weeks","id":"OG006","title":"CTX-471 Combination 0.6 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Analysis Set: all patients who received CTX-471 (and pembrolizumab in combination arms) and had at least 1 post-treatment measurement and no protocol deviations or events affecting the validity of the results","reportingStatus":"POSTED","timeFrame":"Monotherapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose; before Week 9 dose; 1, 6, 24 hours and 2 weeks after Week 9 dose. Combination therapy arms: before Week 1 dose; 1, 6, 24 hours and 2 weeks after Week 1 dose.","title":"Maximum Serum Concentration (Cmax) of CTX-471","type":"SECONDARY","unitOfMeasure":"ng/mL"}